2 Biotech Stocks to Buy Hand Over Fist in December

As the year comes to a close, investors are looking for opportunities to capitalize on the bull market's momentum. Two biotech stocks, Biogen Inc. (BIIB) and Regeneron Pharmaceuticals, Inc. (REGN), have shown strong potential and are poised to deliver impressive returns in December. Both companies have robust pipelines, strategic partnerships, and solid financial health, making them attractive investment options.

Biogen Inc. (BIIB) is a leading biotechnology company focused on developing therapies for neurological and neurodegenerative diseases. With a market cap of $229.9 billion, Biogen's portfolio includes blockbuster drugs like TECFIDERA, VUMERITY, and SPINRAZA, which address critical unmet medical needs. The company's pipeline is also diverse, with promising candidates for Alzheimer's disease, such as ADUHELM, and biosimilars like BENEPALI and IMRALDI. Biogen's strategic partnerships with companies like Eisai, Acorda Therapeutics, and Alkermes Pharma further strengthen its pipeline and growth prospects.

Regeneron Pharmaceuticals, Inc. (REGN) is another biotech stock with significant potential. With a market cap of $85.5 billion, Regeneron's product portfolio includes successful drugs like EYLEA, Dupixent, and Libtayo, which address unmet medical needs in various indications. The company's pipeline is also robust, with several candidates in late-stage development for various indications, including cancer, pain, and infectious diseases. Regeneron's strategic collaborations with Mammoth Biosciences and Sonoma Biotherapeutics are expected to drive innovation and growth in the coming years.

Both Biogen and Regeneron Pharmaceuticals have strong financial health and cash flow management, supporting their investment in R&D and expansion of their product portfolios. Biogen's total cash is $1.7 billion, with a free cash flow of $2.0 billion, while Regeneron's total cash is $9.8 billion, with a free cash flow of $2.2 billion. Their strong cash flow management allows them to invest in R&D and expand their product portfolios, ensuring long-term growth and sustainability.

In conclusion, Biogen Inc. (BIIB) and Regeneron Pharmaceuticals, Inc. (REGN) are two biotech stocks that offer compelling investment opportunities in December. Their robust pipelines, strategic partnerships, and solid financial health make them attractive options for investors looking to capitalize on the bull market's momentum. As the year comes to a close, these two biotech stocks are poised to deliver impressive returns and should be considered for any diversified investment portfolio.